Semaglutide vs Tirzepatide vs Retatrutide: GLP-1 Weight Loss Peptides Compared

Quick Verdict: When comparing semaglutide vs tirzepatide, clinical trial data shows tirzepatide produces greater weight loss (up to 22.5%) than semaglutide (up to 16%), thanks to its dual-receptor mechanism. Retatrutide, the newest triple-agonist peptide, posted even higher numbers at 24% in Phase 2 trials. Each GLP-1 weight loss peptide works differently, and the right choice depends on your research goals.

The GLP-1 peptide space has exploded in the past few years. Researchers now have three distinct compounds to study, each targeting overlapping but different metabolic pathways. This comparison breaks down the clinical data, mechanisms, and practical differences between semaglutide, tirzepatide, and retatrutide so you can make informed decisions for your research.

Semaglutide vs Tirzepatide vs Retatrutide: Quick Comparison

Before diving into the details, here’s a side-by-side snapshot of the three most studied GLP-1 weight loss peptides available for research.

What Is Semaglutide? The Original GLP-1 Weight Loss Peptide

Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk. It mimics the natural incretin hormone GLP-1, which your body releases after eating. By binding to GLP-1 receptors in the brain and gut, it reduces appetite, slows gastric emptying, and improves insulin sensitivity.

Originally approved for type 2 diabetes as Ozempic, semaglutide earned FDA approval for chronic weight management under the brand name Wegovy in 2021. It became the first GLP-1 agonist widely recognized for its weight loss effects.

Semaglutide Clinical Trial Data (STEP Trials)

The STEP (Semaglutide Treatment Effect in People with obesity) trial program provided the foundational data for semaglutide weight loss research. Here are the key findings:

• STEP 1: Participants receiving 2.4 mg semaglutide weekly lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group. The trial enrolled 1,961 adults with obesity or overweight with at least one weight-related comorbidity.
• STEP 2: In adults with type 2 diabetes and overweight/obesity, semaglutide produced 9.6% body weight loss versus 3.4% with placebo. Weight loss was lower in diabetic populations, a pattern seen across all GLP-1 peptides.
• STEP 3: Combined with intensive behavioral therapy, participants lost 16% of body weight—the highest recorded figure in the semaglutide trial program.
• STEP 5: A two-year extension study confirmed that weight loss was maintained as long as treatment continued. Participants who stopped regained most of the weight within a year.

These numbers made semaglutide the gold standard in GLP-1 research. But tirzepatide soon raised the bar.

What Is Tirzepatide? The Dual-Agonist That Changed the Game

Tirzepatide, developed by Eli Lilly, is a dual GIP/GLP-1 receptor agonist. It was the first approved peptide to activate two incretin receptors simultaneously. GIP (glucose-dependent insulinotropic polypeptide) is the other major incretin hormone, and research shows that combining GIP and GLP-1 receptor activation produces stronger metabolic effects than targeting GLP-1 alone.

The GIP component adds several unique benefits. GIP receptor activation appears to enhance fat oxidation, improve lipid metabolism, and amplify the appetite-suppressing effects of GLP-1 signaling. This dual action is why the tirzepatide comparison to semaglutide consistently favors tirzepatide in weight loss outcomes.

Tirzepatide Clinical Trial Data (SURMOUNT Trials)

The SURMOUNT trial program established tirzepatide as the most effective approved weight loss peptide to date:

• SURMOUNT-1: The headline trial. Over 72 weeks, participants on the highest dose (15 mg) lost an average of 22.5% of body weight. Even the lowest dose (5 mg) produced 15% weight loss—roughly matching semaglutide’s best results. The trial enrolled 2,539 adults.
• SURMOUNT-2: In participants with type 2 diabetes, the 15 mg dose produced 14.7% weight loss. This exceeded semaglutide’s performance in diabetic populations (STEP 2) by a wide margin.
• SURMOUNT-3: Combined with intensive lifestyle intervention, tirzepatide produced 26.6% weight loss at the highest dose.
• SURMOUNT-4: A withdrawal study showed that participants who switched from tirzepatide to placebo regained about half their lost weight over 52 weeks, while those who continued treatment maintained their results.

Tirzepatide received FDA approval for type 2 diabetes as Mounjaro in 2022 and for chronic weight management as Zepbound in 2023.

What Is Retatrutide? The Triple-Agonist Frontier

Retatrutide is the newest entry in the GLP-1 peptide lineup and the most aggressive by design. Developed by Eli Lilly, it is a triple agonist that activates three receptors: GLP-1, GIP, and glucagon. This third target—the glucagon receptor—is what sets retatrutide apart from everything before it.

Glucagon receptor activation increases energy expenditure and promotes fat breakdown in the liver. Combined with the appetite suppression of GLP-1 and the metabolic benefits of GIP, this triple mechanism attacks body fat from multiple angles. Research suggests the glucagon component may also help reduce liver fat, a finding with strong implications for metabolic-associated steatotic liver disease (MASLD) research.

For a deeper look at retatrutide’s mechanism, dosing, and research applications, see our complete retatrutide guide.

Retatrutide Clinical Trial Data (Phase 2)

Retatrutide’s Phase 2 trial results, published in the New England Journal of Medicine in 2023, generated major attention:

• Weight loss: Participants on the highest dose (12 mg) lost an average of 24.2% of body weight over 48 weeks. This is the highest weight loss figure recorded in any incretin-based trial to date.
• Dose range: The trial tested doses from 1 mg to 12 mg. Even mid-range doses (8 mg) produced approximately 22% weight loss, exceeding tirzepatide’s SURMOUNT-1 results.
• Liver fat: A notable secondary finding was a significant reduction in liver fat content, supporting research into MASLD treatment applications.
• Trial size: 338 adults with obesity participated. While smaller than the STEP and SURMOUNT programs, the results were statistically significant across all dose groups.

Retatrutide is currently in Phase 3 trials. It does not yet have FDA approval for any indication.

Efficacy: How Much Weight Loss Does Each Peptide Produce?

This is the question most researchers want answered first. Here is a direct comparison of peak weight loss outcomes from each peptide’s primary clinical trials.

A few things stand out. Tirzepatide at its highest dose outperformed semaglutide by roughly 6–7 percentage points. Retatrutide achieved 24% weight loss in just 48 weeks—a shorter trial duration than both STEP and SURMOUNT. Had the retatrutide trial run for 72 weeks, the final number could have been even higher.

It is also worth noting that direct head-to-head trials between these three peptides have not been published. The comparisons above are cross-trial, which means differences in study populations, protocols, and endpoints add some uncertainty. Still, the trend is clear: more receptor targets appear to produce greater weight loss.

How Do Their Mechanisms Differ?

All three peptides belong to the incretin-based therapy family, but they differ in how many metabolic pathways they activate.

Semaglutide: Single-Receptor GLP-1 Agonist

Semaglutide binds exclusively to the GLP-1 receptor. Its effects include reduced appetite through hypothalamic signaling, slowed gastric emptying (making you feel full longer), improved insulin secretion, and reduced glucagon release. This is a well-understood mechanism with years of clinical data behind it.

Tirzepatide: Dual GIP/GLP-1 Agonist

Tirzepatide activates both GLP-1 and GIP receptors. The addition of GIP signaling brings several advantages. GIP receptor activation improves fat metabolism, enhances insulin sensitivity beyond what GLP-1 alone achieves, and appears to reduce the nausea that often accompanies pure GLP-1 agonists. Clinical data suggests that this dual action is why tirzepatide produces weight loss results 40–50% greater than semaglutide.

Retatrutide: Triple GLP-1/GIP/Glucagon Agonist

Retatrutide adds glucagon receptor agonism on top of the GLP-1 and GIP activity. Glucagon has a direct effect on energy expenditure—it tells the body to burn stored fat for fuel. This third mechanism means retatrutide doesn’t just suppress appetite; it actively increases caloric output. The glucagon component also drives liver fat reduction, making retatrutide a subject of active research in metabolic liver disease.

What Are the Side Effects of GLP-1 Peptides?

All three peptides share a similar side effect profile, driven largely by their shared GLP-1 receptor activity. The most commonly reported adverse events across all trials are gastrointestinal.

A notable pattern: tirzepatide tends to produce fewer GI side effects than semaglutide at equivalent efficacy levels. Research suggests this is because the GIP receptor component partially offsets GLP-1-driven nausea. Tirzepatide’s tolerability profile is one of the strongest arguments in the semaglutide vs tirzepatide comparison.

Retatrutide’s side effect data is still limited to Phase 2 trials with smaller sample sizes. The glucagon component adds a unique consideration: increased heart rate was observed at higher doses, though it remained clinically manageable during the trial. Phase 3 data will provide a clearer picture.

Across all three peptides, GI side effects are most common during dose titration and tend to lessen over time. Gradual dose escalation is standard practice in all published protocols.

FDA Approval and Research Status

Understanding where each peptide stands in the regulatory pipeline matters for researchers evaluating long-term study viability.

Semaglutide: Fully Established

Semaglutide has the longest track record. FDA-approved for both diabetes (Ozempic, 2017) and weight management (Wegovy, 2021), it has been studied in tens of thousands of participants across multiple trial programs. The SELECT cardiovascular outcomes trial also demonstrated a 20% reduction in major cardiovascular events, expanding its clinical relevance beyond weight management.

Tirzepatide: Rapidly Expanding

Tirzepatide earned FDA approval for diabetes in 2022 (Mounjaro) and weight management in 2023 (Zepbound). Additional trials are investigating its effects on heart failure, sleep apnea, and MASLD. The SURMOUNT program is one of the largest obesity trial programs ever conducted.

Retatrutide: Early-Stage but Promising

Retatrutide completed Phase 2 trials in 2023 with results published in the New England Journal of Medicine. Phase 3 trials are currently underway. The earliest possible FDA approval would be several years away. For researchers, this means retatrutide represents the frontier of GLP-1 peptide science—the most potent option available but with the least clinical data.

Which GLP-1 Peptide Is Right for Your Research?

The best choice depends on what you’re studying. Here’s a breakdown by research focus.

Choose Semaglutide If:

• You want the most extensively studied GLP-1 agonist with the deepest body of published data
• Your research requires comparison to a well-established reference compound
• You’re studying pure GLP-1 receptor mechanisms without the confounding effects of GIP or glucagon
• Cardiovascular outcome data is relevant to your work (SELECT trial)

Choose Tirzepatide If:

• You’re researching dual incretin receptor interactions and synergy between GLP-1 and GIP pathways
• Maximum weight loss efficacy with FDA-approved status matters for your protocol
• You’re interested in the improved GI tolerability profile compared to single-agonist GLP-1 peptides
• Metabolic research involving both glucose and lipid metabolism is your focus

Choose Retatrutide If:

• You’re investigating the role of glucagon receptor activation in energy expenditure and fat oxidation
• Liver fat reduction and MASLD research are part of your program
• You want to study the highest-potency weight loss peptide currently available for research
• Your work involves multi-receptor incretin pharmacology at the cutting edge of the field

All three research peptides are available through Peptide+: semaglutide in 5mg and 10mg vials, tirzepatide at 10mg, and retatrutide in 5mg and 10mg options.

Frequently Asked Questions

Is tirzepatide more effective than semaglutide for weight loss?

Clinical data suggests yes. In the SURMOUNT-1 trial, tirzepatide at 15 mg produced 22.5% average body weight loss over 72 weeks, compared to 14.9% for semaglutide 2.4 mg in STEP 1 over 68 weeks. The added GIP receptor activity is believed to account for the difference. However, these are cross-trial comparisons—no head-to-head randomized controlled trial has been published comparing the two directly.

What makes retatrutide different from semaglutide and tirzepatide?

Retatrutide activates three receptors (GLP-1, GIP, and glucagon) instead of one or two. The glucagon receptor component is the key differentiator. Glucagon increases energy expenditure by promoting fat breakdown and thermogenesis. This means retatrutide both suppresses caloric intake (like semaglutide and tirzepatide) and increases caloric output. Phase 2 data showed 24.2% weight loss at the highest dose in just 48 weeks. Learn more in our retatrutide guide.

Can you combine semaglutide and tirzepatide?

No published clinical trial has studied combining semaglutide and tirzepatide. Since tirzepatide already includes GLP-1 receptor agonism as part of its dual mechanism, combining it with semaglutide would result in redundant GLP-1 activation and likely increase side effects without proportional benefit. Researchers studying incretin combinations typically focus on pairing incretin agonists with compounds that target different pathways entirely.

How long do GLP-1 peptide results last after stopping treatment?

Clinical data from both the STEP 5 and SURMOUNT-4 trials shows that weight regain begins when treatment stops. In STEP 5, participants who discontinued semaglutide regained approximately two-thirds of their lost weight within one year. SURMOUNT-4 showed that participants switching from tirzepatide to placebo regained about half their weight loss over 52 weeks. This suggests that GLP-1 peptides manage weight rather than permanently reset metabolic set points.

Are GLP-1 peptides safe for long-term use?

Semaglutide has the longest safety track record, with data extending beyond four years in some studies. The SELECT cardiovascular trial (17,604 participants, median follow-up 39.8 months) found no significant safety concerns and demonstrated cardiovascular benefits. Tirzepatide’s long-term data is growing with ongoing extension studies. Retatrutide’s long-term safety profile remains to be established through Phase 3 trials. All three peptides carry warnings regarding thyroid C-cell tumors observed in rodent studies, though this has not been confirmed in humans.

Conclusion: The GLP-1 Peptide Landscape in 2026

The semaglutide vs tirzepatide vs retatrutide comparison comes down to a clear pattern: each successive generation of GLP-1 weight loss peptides targets more receptors and produces greater results. Semaglutide remains the most studied, with the deepest safety data and broadest regulatory approvals. Tirzepatide offers a significant step up in efficacy with strong Phase 3 data and FDA approval. Retatrutide represents the next frontier, with the highest weight loss figures yet seen in clinical trials but still awaiting Phase 3 results.

For researchers, all three compounds offer distinct value. Semaglutide provides a reliable baseline. Tirzepatide demonstrates the power of dual-receptor agonism. Retatrutide opens the door to studying triple-agonist pharmacology and the role of glucagon in metabolic regulation.

Browse the full range of research-grade GLP-1 peptides at Peptide+, including semaglutide, tirzepatide, and retatrutide in multiple vial sizes.